The Inpatient with Cirrhosis: Preventing Decompensation

A Proactive Approach to Managing the Fragile Cirrhotic Patient

Dr Neeraj Manikath , claude.ai

Abstract

Hospitalized patients with cirrhosis represent a uniquely vulnerable population at high risk for acute decompensation, multiorgan failure, and death. The transition from compensated to decompensated cirrhosis dramatically alters prognosis, with median survival dropping from over a decade to less than two years. This review provides a comprehensive, evidence-based approach to the inpatient management of cirrhotic patients, emphasizing prevention of common complications including spontaneous bacterial peritonitis, hepatic encephalopathy, variceal hemorrhage, and hepatorenal syndrome. We discuss prognostic scoring systems, medication safety principles, and specific management strategies for ascites and encephalopathy. Special attention is given to practical "pearls and oysters"—clinical insights that can prevent common pitfalls and improve outcomes in this challenging patient population.

---

Introduction

Cirrhosis affects approximately 4.5 million adults in the United States and accounts for over 50,000 deaths annually.[1] While patients with compensated cirrhosis may remain stable for years, hospitalization often marks a critical inflection point. Any acute illness—infection, gastrointestinal bleeding, medication error, or volume depletion—can precipitate rapid decompensation with devastating consequences.

The concept of acute-on-chronic liver failure (ACLF) has revolutionized our understanding of cirrhosis progression. Studies demonstrate that up to 30% of hospitalized cirrhotics develop ACLF, with mortality rates reaching 50-90% depending on the number of organ failures.[2] This sobering reality underscores the imperative for vigilant, proactive management.

Pearl #1: The moment a cirrhotic patient crosses your threshold, shift from reactive to preventive mode. Most complications are predictable and preventable with systematic attention to detail.

---

The Child-Pugh and MELD-Na Scores at a Glance: Understanding Prognosis

Child-Pugh Classification

The Child-Pugh score, introduced in 1973 and modified thereafter, remains a cornerstone for prognostic assessment.[3] It incorporates five variables: serum bilirubin, albumin, prothrombin time (INR), and clinical assessments of ascites and encephalopathy (Table 1).

Table 1: Child-Pugh Scoring System

Parameter	1 Point	2 Points	3 Points
Bilirubin (mg/dL)	<2	2-3	>3
Albumin (g/dL)	>3.5	2.8-3.5	<2.8
INR	<1.7	1.7-2.3	>2.3
Ascites	None	Mild-moderate	Severe
Encephalopathy	None	Grade 1-2	Grade 3-4

• Class A (5-6 points): 1-year survival ~100%, 2-year survival ~85%
• Class B (7-9 points): 1-year survival ~80%, 2-year survival ~60%
• Class C (10-15 points): 1-year survival ~45%, 2-year survival ~35%[4]

Pearl #2: Child-Pugh C patients admitted to the hospital have a mortality risk exceeding 60% at one year. These patients should trigger early transplant hepatology consultation and goals-of-care discussions.

MELD-Na Score

The Model for End-Stage Liver Disease (MELD), refined to include sodium (MELD-Na), provides objective prognostication and guides transplant allocation.[5] The formula is:

MELD = 3.78×ln[bilirubin (mg/dL)] + 11.2×ln[INR] + 9.57×ln[creatinine (mg/dL)] + 6.43

MELD-Na adjusts for hyponatremia, which independently predicts mortality:

• If Na <125 mmol/L: use 125
• If Na >137 mmol/L: use 137
• MELD-Na = MELD + 1.32×(137-Na) - [0.033×MELD×(137-Na)]

3-Month Mortality by MELD-Na:[6]

• MELD-Na <10: ~2%
• MELD-Na 10-19: ~6%
• MELD-Na 20-29: ~20%
• MELD-Na 30-39: ~50%
• MELD-Na ≥40: ~70%

Oyster #1 (Common Pitfall): Don't calculate MELD scores on patients receiving renal replacement therapy. The creatinine value becomes artificially suppressed, yielding falsely reassuring scores. These patients should be assigned a creatinine of 4.0 mg/dL for MELD calculation.[7]

Pearl #3: A rising MELD-Na during hospitalization—even by 4-5 points—is an ominous sign. It suggests progressive hepatic dysfunction or development of complications and warrants intensified monitoring and specialist consultation.

---

Medication Safety: Navigating the Minefield

Hospitalized cirrhotics are exquisitely sensitive to medications that healthy livers handle with ease. A single dose of the wrong drug can precipitate encephalopathy, renal failure, or bleeding.

Drugs to Avoid or Use with Extreme Caution

1. Sedatives and Opioids

Benzodiazepines, opiates, and other CNS depressants are notorious precipitants of hepatic encephalopathy. Reduced hepatic metabolism and increased blood-brain barrier permeability create a perfect storm.[8]

Pearl #4: If sedation is absolutely necessary, use agents with shorter half-lives and no active metabolites. Lorazepam (carefully dosed) is preferred over diazepam. Better yet, consider non-pharmacologic interventions: reorientation, family presence, music therapy.

Oyster #2: The confused cirrhotic in the ICU doesn't always need sedation—they might need lactulose. Always rule out hepatic encephalopathy before reaching for the Ativan.

2. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

NSAIDs are contraindicated in cirrhosis with ascites. They antagonize diuretic efficacy, precipitate acute kidney injury through renal vasoconstriction, and increase gastrointestinal bleeding risk.[9,10]

Pearl #5: For pain control, acetaminophen remains safe at reduced doses (≤2 grams daily in patients with Child-Pugh A/B; consider ≤1.5 grams in Child-Pugh C).[11] Never use NSAIDs—not even topical preparations, which achieve systemic concentrations.

3. Nephrotoxic Agents

Aminoglycosides, radiocontrast media, and calcineurin inhibitors carry substantial risk in cirrhotics who already have precarious renal perfusion.

Pearl #6: Before ordering CT with contrast, ask: "Does this test change management?" If not, skip it. If necessary, ensure adequate hydration and consider N-acetylcysteine prophylaxis, though evidence in cirrhotics is limited.[12]

4. Anticoagulants

The "auto-anticoagulated" cirrhotic is a myth. Despite prolonged PT/INR, these patients maintain balanced hemostasis through parallel reductions in procoagulant and anticoagulant factors.[13] However, they are neither protected from thrombosis nor immune to bleeding.

Oyster #3: Don't reflexively give fresh frozen plasma (FFP) for elevated INR in stable cirrhotics. INR reflects hepatic synthetic function, not bleeding risk. FFP does not durably correct INR, carries volume overload risk, and is expensive. Reserve it for active bleeding or pre-procedural correction when necessary.[14]

Pearl #7: For VTE prophylaxis, low-dose subcutaneous heparin is generally safe unless platelets <50,000/μL or active bleeding. The risk of portal vein thrombosis and its catastrophic consequences often outweighs bleeding concerns.[15]

Medication Adjustments

Many drugs require dose reduction in cirrhosis. Key examples:

• Propranolol: Start low (10-20 mg BID) and titrate carefully. Target heart rate 55-60 bpm for primary or secondary variceal bleeding prophylaxis.[16]
• Antibiotics: Quinolones, beta-lactams, and third-generation cephalosporins are generally safe. Reduce doses for severe renal impairment.
• Diuretics: Discussed in detail below.

Hack #1: Create a standardized "Cirrhosis Medication Safety Checklist" for admission orders. Include automated alerts for NSAIDs, sedatives, and nephrotoxins in patients with cirrhosis diagnoses.

---

Spontaneous Bacterial Peritonitis Prophylaxis: Who, When, and How

Spontaneous bacterial peritonitis (SBP) complicates 10-30% of hospitalized cirrhotics with ascites and carries mortality rates of 20-40% despite treatment.[17] Prophylaxis is crucial in high-risk populations.

Indications for SBP Prophylaxis

Primary Prophylaxis (prevent first episode):

1. Ascitic fluid protein <1.5 g/dL plus one of the following:[18]

   • Child-Pugh score ≥9 with bilirubin ≥3 mg/dL
   • Serum creatinine ≥1.2 mg/dL
   • Blood urea nitrogen ≥25 mg/dL
   • Serum sodium ≤130 mEq/L

2. Active gastrointestinal bleeding: All cirrhotics with GI bleeding should receive antibiotic prophylaxis, as bacterial infections occur in 20% and worsen outcomes.[19]

Secondary Prophylaxis (prevent recurrence):

• Any prior SBP episode warrants lifelong prophylaxis, as recurrence risk approaches 70% at one year without prophylaxis.[20]

Antibiotic Selection

First-line: Norfloxacin 400 mg PO daily (reduces SBP risk by 50-60%)[21]

Alternatives:

• Ciprofloxacin 750 mg PO weekly (non-inferior to daily norfloxacin)[22]
• Trimethoprim-sulfamethoxazole DS daily (5 days/week)[23]
• Rifaximin (emerging data, but not yet standard)[24]

For GI bleeding: Ceftriaxone 1 gram IV daily for 7 days is superior to oral quinolones in preventing infections and is preferred in advanced cirrhosis (Child-Pugh C, serum bilirubin >3 mg/dL).[25]

Pearl #8: Don't wait for formal diagnostic paracentesis to start prophylaxis in appropriate candidates. If ascites is clinically evident and risk factors are present, initiate empiric prophylaxis while awaiting paracentesis.

Oyster #4: Not every cirrhotic with ascites needs SBP prophylaxis. Low-risk patients (ascitic protein >1.5 g/dL, normal renal function, Child-Pugh A) do not benefit from routine prophylaxis and face unnecessary antibiotic exposure and resistance concerns.[26]

Pearl #9: In patients already on quinolones for SBP prophylaxis who develop peritonitis, organisms are often quinolone-resistant. Empiric treatment should include third-generation cephalosporins (cefotaxime 2 grams IV Q8H) rather than fluoroquinolones.[27]

---

Managing Ascites: The Art and Science

Ascites develops in approximately 60% of patients within 10 years of cirrhosis diagnosis and marks transition to decompensated disease.[28] Management requires balancing fluid removal against precipitating hepatorenal syndrome.

Initial Assessment

Every hospitalized cirrhotic with new or worsening ascites requires diagnostic paracentesis to exclude SBP.[29] There is no INR or platelet threshold that absolutely contraindicates paracentesis—bleeding risk is <1% even with INR >2 and platelets >20,000.[30]

Pearl #10: "Blind" diagnostic paracentesis is safe. You don't need ultrasound guidance for ascites that is clinically detectable. Save ultrasound for difficult or loculated fluid collections.

Essential Ascitic Fluid Studies:

• Cell count with differential (PMN count is critical)
• Culture in blood culture bottles at bedside (increases sensitivity to 80-90%)[31]
• Total protein and albumin (calculate SAAG)
• Gram stain (low sensitivity, but do it anyway)

Serum-Ascites Albumin Gradient (SAAG):

• SAAG ≥1.1 g/dL: Portal hypertension (97% accuracy)[32]
• SAAG <1.1 g/dL: Consider peritoneal carcinomatosis, tuberculosis, pancreatitis, nephrotic syndrome

SBP Diagnosis: PMN count ≥250 cells/μL, even with negative culture (culture-negative neutrocytic ascites).[33]

Medical Management

1. Dietary Sodium Restriction

Restrict sodium to 2 grams (88 mmol) daily. This alone achieves negative sodium balance in 10-20% of patients.[34]

Hack #2: Teach patients to read labels. A single serving of canned soup can contain 1,500 mg sodium—nearly the entire daily allowance.

2. Diuretic Therapy

The combination of spironolactone (aldosterone antagonist) plus furosemide is standard, typically initiated in a 100:40 mg ratio.[35]

Starting regimen:

• Spironolactone 100 mg PO daily + Furosemide 40 mg PO daily
• Monitor weight, electrolytes, and renal function every 2-3 days
• Target weight loss: 0.5 kg/day (without peripheral edema) or 1 kg/day (with edema)[36]

Escalation:

• Increase both diuretics simultaneously in 100:40 ratio every 3-5 days
• Maximum doses: Spironolactone 400 mg, Furosemide 160 mg

Pearl #11: Cirrhotics mobilize ascites slowly—no more than 500-700 mL/day from the peritoneal cavity. More aggressive diuresis depletes intravascular volume faster than ascites can refill it, precipitating prerenal azotemia and hepatorenal syndrome.

Oyster #5: The patient with peripheral edema and ascites can safely lose 1-2 kg daily, as peripheral edema mobilizes into the vascular space. But once peripheral edema resolves, slow down to 0.5 kg/day to avoid intravascular volume depletion.

Monitoring parameters:

• Stop diuretics if: Creatinine rises >2 mg/dL, sodium <120 mEq/L, severe hypokalemia or hyperkalemia develops, or encephalopathy worsens
• Refractory ascites: Defined as ascites that cannot be mobilized or recurs rapidly despite maximal diuretic therapy and sodium restriction[37]

3. Large-Volume Paracentesis (LVP)

For tense ascites causing dyspnea or discomfort, or for refractory ascites, LVP is first-line therapy.[38]

Technique:

• Can safely remove up to 5-6 liters per session
• Albumin replacement: 6-8 grams of albumin per liter removed if >5 liters drained (prevents post-paracentesis circulatory dysfunction)[39]
• For <5 liters, albumin replacement is controversial but often omitted

Pearl #12: Complete large-volume paracentesis (removing all accessible fluid) is safe, well-tolerated, and provides faster symptom relief than serial small-volume taps.[40]

Pearl #13: Post-paracentesis, resume or continue diuretics to delay recurrence. The notion that diuretics should be held after paracentesis is outdated.[41]

Refractory Ascites Management

When medical therapy fails:

1. Repeated LVP (every 2-4 weeks) with albumin replacement
2. Transjugular intrahepatic portosystemic shunt (TIPS): Consider in appropriate candidates (Child-Pugh <12, MELD <18) who require frequent paracentesis[42]
3. Liver transplantation evaluation: Refractory ascites is a marker of advanced disease and warrants urgent referral

Oyster #6: TIPS is not a panacea. It can precipitate or worsen hepatic encephalopathy in 30-40% of patients and is contraindicated in severe liver failure, heart failure, and pulmonary hypertension.[43]

---

Hepatic Encephalopathy: Identifying and Treating Precipitants

Hepatic encephalopathy (HE) affects up to 45% of cirrhotics at some point and significantly increases mortality.[44] In the inpatient setting, HE is rarely "spontaneous"—there is almost always an identifiable precipitant.

Grading Hepatic Encephalopathy

West Haven Criteria:[45]

• Grade 0 (Minimal HE): Subclinical, detected only by psychometric testing
• Grade 1: Trivial lack of awareness, shortened attention span, sleep disturbance
• Grade 2: Lethargy, disorientation, inappropriate behavior, asterixis
• Grade 3: Somnolent but arousable, gross disorientation, bizarre behavior
• Grade 4: Coma, unresponsive to painful stimuli

Pearl #14: Asterixis is specific but insensitive. Its absence does not exclude HE. Subtle changes in sleep-wake cycle, attention, or handwriting may be the only early clues.

The Systematic Search for Precipitants

When HE develops or worsens, always investigate these precipitants:

1. Infection (Most Common)

Up to 50% of HE episodes are triggered by infection, most commonly SBP, urinary tract infection, pneumonia, or cellulitis.[46]

Work-up:

• Diagnostic paracentesis (rule out SBP)
• Urinalysis and culture
• Chest X-ray
• Blood cultures
• Consider Clostridioides difficile if recent antibiotics or diarrhea

Pearl #15: Treat suspected SBP empirically with cefotaxime 2 grams IV Q8H while awaiting culture results. Albumin (1.5 g/kg within 6 hours, then 1 g/kg on day 3) reduces renal impairment and mortality in SBP.[47]

2. Gastrointestinal Bleeding

Blood in the gut is metabolized to ammonia by colonic bacteria, precipitating HE. Even modest bleeding can trigger encephalopathy.

Work-up:

• Hemoglobin/hematocrit
• Stool guaiac or immunochemical test
• Consider nasogastric lavage if upper GI bleeding suspected
• Urgent endoscopy if overt bleeding

Pearl #16: Octreotide (50 mcg IV bolus, then 50 mcg/hr infusion) and antibiotics (ceftriaxone 1 gram IV daily) should be initiated immediately in suspected variceal bleeding, even before endoscopy.[48]

3. Electrolyte Disturbances

• Hypokalemia: Alkalosis enhances ammonia entry into the brain
• Hyponatremia: Causes cerebral edema
• Alkalosis: Shifts ammonia equilibrium toward more permeable NH3

Pearl #17: Aggressive potassium repletion in cirrhotics on diuretics is essential. Target potassium 4.0-5.0 mEq/L to prevent alkalosis-mediated HE.

4. Medications

Review for recent introduction of sedatives, opioids, or anticholinergics.

5. Constipation

Reduced colonic transit time increases ammonia absorption.

Pearl #18: Daily bowel movements are therapeutic in cirrhosis. Lactulose should be titrated to achieve 2-3 soft stools per day, not just one.

6. Volume Depletion

Overly aggressive diuresis or inadequate oral intake precipitates azotemia, which worsens HE.

7. Portosystemic Shunt

TIPS or large spontaneous shunts divert ammonia and other toxins away from hepatic clearance.

Oyster #7: Don't forget zinc deficiency. Cirrhotic patients are often zinc-depleted, and zinc is a cofactor for ammonia metabolism. Supplementation (220 mg zinc sulfate BID) may help refractory HE, though evidence is limited.[49]

Treatment of Hepatic Encephalopathy

First-Line: Lactulose

• Loading: 45 mL PO every 2 hours until first bowel movement, then 15-45 mL PO BID-TID
• Goal: 2-3 soft, acidic stools per day
• Mechanism: Acidifies colon (traps ammonia as NH4+), acts as cathartic, modulates gut microbiome[50]

Pearl #19: Lactulose works, but it takes time. Don't abandon it after one dose. Give it 24-48 hours to show effect while addressing precipitants.

For severe HE or intolerance: Lactulose enemas (300 mL in 700 mL water, retain 30-60 minutes) can be used.

Second-Line: Rifaximin

• Dose: 550 mg PO BID
• Mechanism: Non-absorbable antibiotic that reduces ammonia-producing gut bacteria
• Efficacy: Reduces HE recurrence by ~50% when added to lactulose[51]
• Cost: Expensive; reserve for recurrent or refractory HE

Adjunctive Measures:

• Protein restriction is outdated: Maintain normal protein intake (1.2-1.5 g/kg/day). Malnutrition worsens outcomes.[52]
• Branched-chain amino acids: May help in refractory cases or protein-intolerant patients, but evidence is mixed[53]

Pearl #20: The airway comes first. Grade 3-4 HE patients may require intubation for airway protection. Don't delay for "one more dose" of lactulose if the patient is obtunded and at aspiration risk.

---

Additional Inpatient Pearls

Renal Function Monitoring

Acute kidney injury in cirrhosis has multiple etiologies: prerenal azotemia from volume depletion, hepatorenal syndrome (HRS), acute tubular necrosis, or drug-induced nephrotoxicity.

Hepatorenal Syndrome Diagnostic Criteria (ICA-AKI Criteria):[54]

• Cirrhosis with ascites
• AKI per KDIGO criteria
• No response to 2 days of diuretic withdrawal and albumin challenge (1 g/kg, max 100 g/day)
• No shock, nephrotoxins, or parenchymal kidney disease (proteinuria <500 mg/day, no hematuria, normal renal ultrasound)

Treatment of HRS:

• Vasoconstrictor therapy: Midodrine (starting 7.5 mg PO TID, titrate to max 15 mg TID) + octreotide (100-200 mcg SC TID) + albumin (1 g/kg day 1, then 20-40 g/day)[55]
• Alternative: Terlipressin (not FDA-approved in US but used internationally)[56]
• Renal replacement therapy as bridge to transplant if needed
• TIPS in select cases

Pearl #21: Early HRS recognition is critical. Every 0.3 mg/dL creatinine rise in a cirrhotic should prompt diuretic reassessment and consideration of albumin challenge.

Nutrition

Cirrhotic patients are commonly malnourished, which independently predicts mortality.[57]

Recommendations:

• Protein: 1.2-1.5 g/kg/day (plant and dairy proteins preferable)
• Calories: 35-40 kcal/kg/day
• Late-evening snack: Reduces overnight catabolism (complex carbohydrate + protein)[58]
• Avoid prolonged fasting: Cirrhotics rapidly enter catabolic states

Pearl #22: The "protein-free diet" for HE is obsolete and harmful. Adequate protein intake is essential for recovery and prevents sarcopenia, a major prognostic factor.[59]

Coagulopathy Management

Pearl #23: Avoid routine correction of INR in stable cirrhotics. The INR does not reflect bleeding risk accurately in cirrhosis. For procedures:

• Paracentesis/thoracentesis: No correction needed
• Upper endoscopy: No correction needed
• Central line placement: Consider correction if INR >2.5 or platelets <30,000, though data are limited[60]

Vaccination

Inpatient admission provides opportunity for vaccination:

• Hepatitis A and B: If non-immune (check titers)
• Pneumococcal: PCV20 or PCV15 + PPSV23
• Influenza: Annually
• COVID-19: Per current recommendations

---

Summary: A Checklist Approach to the Hospitalized Cirrhotic

On Admission: ☐ Calculate Child-Pugh and MELD-Na scores ☐ Review and discontinue NSAIDs, sedatives, nephrotoxins ☐ Diagnostic paracentesis if ascites present (new or worsening) ☐ Initiate or verify SBP prophylaxis if indicated ☐ Assess nutrition and initiate protein-adequate diet ☐ VTE prophylaxis (subcutaneous heparin unless contraindicated) ☐ Check variceal bleeding history; ensure beta-blocker if indicated ☐ Hepatology consultation for MELD-Na ≥15 or Child-Pugh B/C

Daily Monitoring: ☐ Weight, strict I/O ☐ Electrolytes, renal function ☐ Assess for precipitants if HE present or develops ☐ Review bowel movements (goal: 2-3 soft stools/day with lactulose) ☐ Monitor for infection (fever, leukocytosis, clinical deterioration)

Prior to Discharge: ☐ Medication reconciliation (eliminate unsafe drugs) ☐ Ensure outpatient hepatology follow-up within 1-2 weeks ☐ Discuss transplant evaluation if appropriate (MELD ≥15) ☐ Prescribe lactulose, rifaximin, SBP prophylaxis, beta-blocker as appropriate ☐ Dietary counseling (low sodium) ☐ Educate on red-flag symptoms (confusion, bleeding, fever, abdominal pain)

---

Conclusion

The hospitalized cirrhotic patient requires a paradigm shift from reactive to proactive management. Complications such as SBP, hepatic encephalopathy, variceal bleeding, and renal failure are predictable and often preventable with systematic vigilance. Familiarity with prognostic scores, strict medication safety protocols, appropriate prophylaxis strategies, and careful management of ascites and encephalopathy precipitants can substantially reduce morbidity and mortality. Every cirrhotic admission is an opportunity—to prevent decompensation, optimize treatment, and potentially bridge a patient to transplantation and long-term survival.

---

References

1. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151-171.

2. Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426-1437.

3. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646-649.

4. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217-231.

5. Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology. 2007;45(3):797-805.

6. Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359(10):1018-1026.

7. Leise MD, Kim WR, Kremers WK, et al. A revised model for end-stage liver disease optimizes prediction of mortality among patients awaiting liver transplantation. Gastroenterology. 2011;140(7):1952-1960.

8. Bustamante J, Rimola A, Ventura PJ, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol. 1999;30(5):890-895.

9. Gentilini P, Romanelli RG, Laffi G, et al. Cardiovascular and renal effects of NSAIDs in liver cirrhosis. Hepatogastroenterology. 1997;44(16):1057-1063.

10. Garcia Rodriguez LA, Hernandez-Diaz S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res. 2001;3(2):98-101.

11. Benson GD, Koff RS, Tolman KG. The therapeutic use of acetaminophen in patients with liver disease. Am J Ther. 2005;12(2):133-141.

12. Huber W, Schipek C, Ilgmann K, et al. Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency. Am J Cardiol. 2003;91(10):1157-1162.

13. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365(2):147-156.

14. Stanworth SJ, Walsh TS, Prescott RJ, et al. A national study of plasma use in critical care: clinical indications, dose and effect on prothrombin time. Crit Care. 2011;15(2):R108.

15. Northup PG, McMahon MM, Ruhl AP, et al. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol. 2006;101(7):1524-1528.

16. Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65(1):310-335.

17. Fernández J, Navasa M, Gómez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology. 2002;35(1):140-148.

18. Runyon BA; AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;49(6):2087-2107.

19. Bernard B, Grangé JD, Khac EN, et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology. 1999;29(6):1655-1661.

20. Ginés P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology. 1990;12(4 Pt 1):716-724.

21. Fernández J, Ruiz del Arbol L, Gómez C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology. 2006;131

(4):1049-1056.

22. Elfert A, Abo Ali L, Soliman S, et al. Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol. 2016;28(12):1450-1454.

23. Terg R, Llano K, Cobas SM, et al. Effects of oral ciprofloxacin on aerobic gram-negative fecal flora in patients with cirrhosis: results of short- and long-term administration, with daily and weekly dosages. J Hepatol. 1998;29(3):437-442.

24. Assem M, Elsabaawy M, Abdelrashed M, et al. Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study. Hepatol Int. 2016;10(2):377-385.

25. Fernández J, Ruiz del Arbol L, Gómez C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology. 2006;131(4):1049-1056.

26. Runyon BA. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterology. 1986;91(6):1343-1346.

27. Umgelter A, Reindl W, Miedaner M, et al. Failure of current antibiotic first-line regimens and mortality in hospitalized patients with spontaneous bacterial peritonitis. Infection. 2009;37(1):2-8.

28. Ginès P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology. 1987;7(1):122-128.

29. Runyon BA. Management of adult patients with ascites due to cirrhosis: update 2012. AASLD Practice Guidelines. Hepatology. 2013;57(4):1651-1653.

30. Pache I, Bilodeau M. Severe haemorrhage following abdominal paracentesis for ascites in patients with liver disease. Aliment Pharmacol Ther. 2005;21(5):525-529.

31. Runyon BA, Canawati HN, Akriviadis EA. Optimization of ascitic fluid culture technique. Gastroenterology. 1988;95(5):1351-1355.

32. Runyon BA, Montano AA, Akriviadis EA, et al. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med. 1992;117(3):215-220.

33. Runyon BA; AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;49(6):2087-2107.

34. Reynolds TB, Lieberman FL, Goodman AR. Advantages of treatment of ascites without sodium restriction and without complete removal of excess fluid. Gut. 1978;19(6):549-553.

35. Santos J, Planas R, Pardo A, et al. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. J Hepatol. 2003;39(2):187-192.

36. Runyon BA. Management of adult patients with ascites due to cirrhosis: update 2012. AASLD Practice Guidelines. Hepatology. 2013;57(4):1651-1653.

37. Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut. 2006;55 Suppl 6:vi1-12.

38. Ginès P, Arroyo V, Quintero E, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology. 1987;93(2):234-241.

39. Ginès A, Fernández-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology. 1996;111(4):1002-1010.

40. Ginès P, Titó L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology. 1988;94(6):1493-1502.

41. Moreau R, Delegue P, Pessione F, et al. Clinical characteristics and outcome of patients with cirrhosis and refractory ascites. Liver Int. 2004;24(5):457-464.

42. Bureau C, Thabut D, Oberti F, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology. 2017;152(1):157-163.

43. Rossle M, Ochs A, Gulberg V, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med. 2000;342(23):1701-1707.

44. Bustamante J, Rimola A, Ventura PJ, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol. 1999;30(5):890-895.

45. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35(3):716-721.

46. Shawcross DL, Davies NA, Williams R, Jalan R. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol. 2004;40(2):247-254.

47. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341(6):403-409.

48. Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65(1):310-335.

49. Riggio O, Merli M, Capocaccia L, et al. Zinc supplementation reduces blood ammonia and increases liver ornithine transcarbamylase activity in experimental cirrhosis. Hepatology. 1992;16(3):785-789.

50. Bajaj JS, Schubert CM, Heuman DM, et al. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology. 2010;138(7):2332-2340.

51. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071-1081.

52. Cordoba J, López-Hellín J, Planas M, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol. 2004;41(1):38-43.

53. Marchesini G, Bianchi G, Merli M, et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology. 2003;124(7):1792-1801.

54. Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62(4):968-974.

55. Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008;134(5):1360-1368.

56. Martin-Llahi M, Pépin MN, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008;134(5):1352-1359.

57. Merli M, Lucidi C, Giannelli V, et al. Cirrhotic patients are at risk for health care-associated bacterial infections. Clin Gastroenterol Hepatol. 2010;8(11):979-985.

58. Plank LD, Gane EJ, Peng S, et al. Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial. Hepatology. 2008;48(2):557-566.

59. Tandon P, Ney M, Irwin I, et al. Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. Liver Transpl. 2012;18(10):1209-1216.

60. Napolitano G, Iacobellis A, Merla A, et al. Bleeding after invasive procedures is rare and unpredicted by platelet counts in cirrhotic patients with thrombocytopenia. Eur J Intern Med. 2017;38:79-82.

Disclosures: None

Acknowledgments: The author thanks the Department of Internal Medicine for support in preparing this manuscript.